NASDAQ:RZLT Rezolute (RZLT) Stock Price, News & Analysis → The CHIPS Act Motherlode (From True Market Insiders) (Ad) Free RZLT Stock Alerts $2.64 +0.08 (+3.13%) (As of 05/17/2024 ET) Add Compare Share Share Today's Range$2.51▼$2.7350-Day Range$1.78▼$3.5452-Week Range$0.72▼$3.69Volume213,986 shsAverage Volume268,366 shsMarket Capitalization$105.94 millionP/E RatioN/ADividend YieldN/APrice Target$8.80 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media Get Rezolute alerts: Email Address Rezolute MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside233.3% Upside$8.80 Price TargetShort InterestHealthy0.78% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.17Based on 11 Articles This WeekInsider TradingAcquiring Shares$242,961 Bought Last QuarterProj. Earnings GrowthDecreasingFrom ($1.12) to ($1.16) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.89 out of 5 starsMedical Sector326th out of 921 stocksPharmaceutical Preparations Industry141st out of 418 stocks 3.5 Analyst's Opinion Consensus RatingRezolute has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageRezolute has only been the subject of 4 research reports in the past 90 days.Read more about Rezolute's stock forecast and price target. Previous Next 3.0 Short Interest Percentage of Shares Shorted0.78% of the outstanding shares of Rezolute have been sold short.Short Interest Ratio / Days to CoverRezolute has a short interest ratio ("days to cover") of 0.9, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Rezolute has recently increased by 29.75%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldRezolute does not currently pay a dividend.Dividend GrowthRezolute does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for RZLT. Previous Next 1.8 News and Social Media Coverage News SentimentRezolute has a news sentiment score of 0.17. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.43 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 11 news articles for Rezolute this week, compared to 1 article on an average week.Search InterestOnly 7 people have searched for RZLT on MarketBeat in the last 30 days. This is a decrease of -65% compared to the previous 30 days.MarketBeat FollowsOnly 9 people have added Rezolute to their MarketBeat watchlist in the last 30 days. This is a decrease of -25% compared to the previous 30 days. Previous Next 5.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Rezolute insiders have bought more of their company's stock than they have sold. Specifically, they have bought $242,961.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders20.80% of the stock of Rezolute is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions82.97% of the stock of Rezolute is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Rezolute's insider trading history. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Rezolute are expected to decrease in the coming year, from ($1.12) to ($1.16) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Rezolute is -2.32, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Rezolute is -2.32, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioRezolute has a P/B Ratio of 1.49. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Rezolute's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad True Market InsidersThe CHIPS Act MotherlodeIf you haven’t heard yet, the CHIPS Act is the US government pouring $280 BILLION into the manufacturing of US semiconductors. A lot of companies will make a fortune from this.Click here to see my #1 investment for 2024. About Rezolute Stock (NASDAQ:RZLT)Rezolute, Inc., a clinical stage biopharmaceutical company, develops therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder. It is also developing RZ402, an oral plasma kallikrein inhibitor, which is in clinical trial for the chronic treatment of diabetic macular edema. The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, Inc. in December 2017. Rezolute, Inc. was incorporated in 2010 and is headquartered in Redwood City, California.Read More RZLT Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart RZLT Stock News HeadlinesMay 18 at 5:36 AM | americanbankingnews.comRezolute (NASDAQ:RZLT) Rating Reiterated by HC WainwrightMay 17 at 2:45 PM | markets.businessinsider.comBuy Rating on Rezolute: Unrecognized Potential in DME Treatment and Advancements in RZ358 for HyperinsulinismMay 17 at 2:45 PM | markets.businessinsider.comBuy Rating Affirmed on Rezolute’s Solid Financials and Advancing Clinical TrialsMay 16 at 7:58 PM | markets.businessinsider.comBuy Rating Affirmed for Rezolute Amidst Clinical Progress and Market OpportunityMay 16 at 2:57 PM | finanznachrichten.deRezolute, Inc.: Rezolute Reports Third Quarter Fiscal 2024 Financial Results and Provides Business UpdateMay 16 at 12:06 AM | investorplace.comRZLT Stock Earnings: Rezolute Misses EPS for Q3 2024May 15, 2024 | globenewswire.comRezolute Reports Third Quarter Fiscal 2024 Financial Results and Provides Business UpdateMay 12, 2024 | nasdaq.comRezolute, Inc. Common Stock (NV) (RZLT) NewsMay 10, 2024 | finance.yahoo.comRezolute, Inc. (NASDAQ:RZLT) has caught the attention of institutional investors who hold a sizeable 47% stakeApril 23, 2024 | globenewswire.comPhase 2 RIZE Study Sub-Analyses to be Presented at the 2024 Pediatric Endocrine Society Annual MeetingApril 19, 2024 | msn.comJonesTrading Initiates Coverage of Rezolute (RZLT) with Buy RecommendationApril 18, 2024 | markets.businessinsider.comOptimistic Buy Rating for Rezolute’s RZ402 Drug Candidate Amid Promising DME Treatment ProspectsApril 15, 2024 | investorplace.comCan You Afford to Ignore These 3 Biotech Stocks Up Over 160% in 2024?April 10, 2024 | benzinga.comRezolute Stock (NASDAQ:RZLT), Analyst Ratings, Price Targets, PredictionsApril 4, 2024 | insidermonkey.comInsiders Are Buying These 5 Penny StocksMarch 27, 2024 | finance.yahoo.comRezolute Reaches US$75m Market Cap Benefiting Insider Stock BuyingMarch 20, 2024 | investing.comRezolute's chief medical officer buys $18.8k in company stockMarch 6, 2024 | globenewswire.comRezolute Reports Validation of the Potential Use of RZ358 for Treatment of Non-Islet Cell Tumor Hypoglycemia (NICTH)February 22, 2024 | benzinga.comRezolute Stock (NASDAQ:RZLT) Earnings Dates and Earning CallsFebruary 16, 2024 | finanznachrichten.deRezolute, Inc.: Rezolute Reports Second Quarter Fiscal 2024 Results and Provides Business UpdateFebruary 15, 2024 | finance.yahoo.comWe're Keeping An Eye On Rezolute's (NASDAQ:RZLT) Cash Burn RateFebruary 13, 2024 | finance.yahoo.comRezolute Reports Second Quarter Fiscal 2024 Results and Provides Business UpdateFebruary 8, 2024 | markets.businessinsider.comBuy Rating Affirmed for Rezolute’s RZ358 Based on Untapped Market Potential and Therapeutic EfficacyJanuary 24, 2024 | msn.comRezolute appoints Daron Evans as CFOJanuary 23, 2024 | msn.comRezolute secures innovation passport designation from U.K. for RZ358 treating hypoglycemiaSee More Headlines Receive RZLT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Rezolute and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings9/14/2023Today5/19/2024Fiscal Year End6/30/2024Next Earnings (Estimated)9/12/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:RZLT CUSIPN/A CIK1509261 Webwww.rezolutebio.com Phone(650) 206-4507FaxN/AEmployees57Year FoundedN/APrice Target and Rating Average Stock Price Target$8.80 High Stock Price Target$14.00 Low Stock Price Target$5.00 Potential Upside/Downside+233.3%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($1.14) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-51,790,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-60.90% Return on Assets-54.58% Debt Debt-to-Equity RatioN/A Current Ratio11.82 Quick Ratio12.00 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.77 per share Price / Book1.49Miscellaneous Outstanding Shares40,130,000Free Float31,781,000Market Cap$105.94 million OptionableNot Optionable Beta1.29 20 Stocks to Sell NowMarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.Get This Free Report Key ExecutivesMr. Nevan Charles Elam J.D. (Age 57)Founder, CEO & Acting Chairman of the Board Comp: $973.65kDr. Brian Kenneth Roberts M.D. (Age 48)Chief Medical Officer Comp: $738.86kMr. Daron G. Evans M.B.A. (Age 50)M.S., Chief Financial Officer Dr. Davelyn Eaves Hood M.B.A.M.D., Director and Head of Scientific & Patient AffairsMr. Michael R. DeperroSenior VP & Head of Corporate DevelopmentMr. Michael CovarrubiasSenior VP & Head of Program & Portfolio ManagementMr. Chris MilksVP & Head of FinanceDr. Raj Agrawal M.D.VP & Head of Ophthalmological Clinical DevelopmentMs. Robyn SweinhartVP & Head of QualityMs. Erin O'BoyleSenior VP & Head of Clinical OperationsMore ExecutivesKey CompetitorsCellectar BiosciencesNASDAQ:CLRBAbeona TherapeuticsNASDAQ:ABEOImmunicNASDAQ:IMUXAdageneNASDAQ:ADAGFibroGenNASDAQ:FGENView All CompetitorsInsiders & InstitutionsAffinity Asset Advisors LLCBought 1,600,000 shares on 5/15/2024Ownership: 3.987%Vanguard Group Inc.Bought 145,700 shares on 5/10/2024Ownership: 3.871%Acadian Asset Management LLCBought 90,346 shares on 5/10/2024Ownership: 0.225%Rosalind Advisors Inc.Bought 200,000 shares on 4/25/2024Ownership: 0.498%Vivo Capital LLCSold 445,138 shares on 4/22/2024Ownership: 6.972%View All Insider TransactionsView All Institutional Transactions RZLT Stock Analysis - Frequently Asked Questions Should I buy or sell Rezolute stock right now? 5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Rezolute in the last year. There are currently 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" RZLT shares. View RZLT analyst ratings or view top-rated stocks. What is Rezolute's stock price target for 2024? 5 brokerages have issued 12-month target prices for Rezolute's shares. Their RZLT share price targets range from $5.00 to $14.00. On average, they anticipate the company's stock price to reach $8.80 in the next year. This suggests a possible upside of 233.3% from the stock's current price. View analysts price targets for RZLT or view top-rated stocks among Wall Street analysts. How have RZLT shares performed in 2024? Rezolute's stock was trading at $0.9925 on January 1st, 2024. Since then, RZLT shares have increased by 166.0% and is now trading at $2.64. View the best growth stocks for 2024 here. When is Rezolute's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, September 12th 2024. View our RZLT earnings forecast. How were Rezolute's earnings last quarter? Rezolute, Inc. (NASDAQ:RZLT) released its quarterly earnings results on Thursday, September, 14th. The company reported ($0.25) earnings per share for the quarter, beating the consensus estimate of ($0.36) by $0.11. What other stocks do shareholders of Rezolute own? Based on aggregate information from My MarketBeat watchlists, some companies that other Rezolute investors own include Fulcrum Therapeutics (FULC), VIVUS (VVUS), Acasti Pharma (ACST), CymaBay Therapeutics (CBAY), Entasis Therapeutics (ETTX), Akero Therapeutics (AKRO), Cumberland Pharmaceuticals (CPIX), Evofem Biosciences (EVFM) and Evelo Biosciences (EVLO). Who are Rezolute's major shareholders? Rezolute's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Vivo Capital LLC (6.97%), Affinity Asset Advisors LLC (3.99%), Vanguard Group Inc. (3.87%), Rosalind Advisors Inc. (0.50%) and Acadian Asset Management LLC (0.23%). Insiders that own company stock include Brian Kenneth Roberts, Daron Evans, Genexine Inc, Gil M Labrucherie, Nevan C Elam and Young-Jin Kim. View institutional ownership trends. How do I buy shares of Rezolute? Shares of RZLT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:RZLT) was last updated on 5/19/2024 by MarketBeat.com Staff From Our PartnersCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill Publishing[URGENT] DO NOT Touch These AI Stocks!Weiss RatingsForget Bitcoin: This $8 Stock Is the Next Big ThingBehind the MarketsShocking $16T Elon Musk Crypto LeakCrypto 101 MediaDems have chosen Biden replacement?Paradigm PressExposed: 10 CENT Crypto to Explode May 20th?True Market InsidersPOTUS in ‘25 Not Biden/Trump, ButThe Freeport Society41 banks launch ‘crypto dollar’Stansberry Research Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Rezolute, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.